The early clinical trials based on adoptive cell transfer, utilized lymphokine-activated killer (LAK) cells generated from autologous PBMCs cultured in vitro with high doses IL-2 for 3–7 days in order to induce anti-tumor killer cells that mainly consisted of NK cells (57–59). Here, IL2 is linked to neoplasm.